Your browser doesn't support javascript.
loading
People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination.
Gainullin, Murat; Federico, Lorenzo; Røkke Osen, Julie; Chaban, Viktoriia; Kared, Hassen; Alirezaylavasani, Amin; Lund-Johansen, Fridtjof; Wildendahl, Gull; Jacobsen, Jon-Aksel; Sarwar Anjum, Hina; Stratford, Richard; Tennøe, Simen; Malone, Brandon; Clancy, Trevor; Vaage, John T; Henriksen, Kathleen; Wüsthoff, Linda; Munthe, Ludvig A.
Afiliação
  • Gainullin M; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Federico L; NEC OncoImmunity AS, Oslo, Norway.
  • Røkke Osen J; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Chaban V; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Kared H; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Alirezaylavasani A; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Lund-Johansen F; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Wildendahl G; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Jacobsen JA; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Sarwar Anjum H; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Stratford R; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Tennøe S; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Malone B; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Clancy T; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Vaage JT; ImmunoLingo Convergence Center, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Henriksen K; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Wüsthoff L; Agency for Social and Welfare Services, Oslo, Norway.
  • Munthe LA; Agency for Social and Welfare Services, Oslo, Norway.
Front Immunol ; 14: 1235210, 2023.
Article em En | MEDLINE | ID: mdl-38299149
ABSTRACT
People who use drugs (PWUD) are at a high risk of contracting and developing severe coronavirus disease 2019 (COVID-19) and other infectious diseases due to their lifestyle, comorbidities, and the detrimental effects of opioids on cellular immunity. However, there is limited research on vaccine responses in PWUD, particularly regarding the role that T cells play in the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we show that before vaccination, PWUD did not exhibit an increased frequency of preexisting cross-reactive T cells to SARS-CoV-2 and that, despite the inhibitory effects that opioids have on T-cell immunity, standard vaccination can elicit robust polyfunctional CD4+ and CD8+ T-cell responses that were similar to those found in controls. Our findings indicate that vaccination stimulates an effective immune response in PWUD and highlight targeted vaccination as an essential public health instrument for the control of COVID-19 and other infectious diseases in this group of high-risk patients.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doenças Transmissíveis / COVID-19 Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Noruega

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doenças Transmissíveis / COVID-19 Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Noruega